Savara Inc (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Analysts

Savara Inc (NASDAQ:SVRA) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $9.86.

Several research analysts have weighed in on the stock. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright decreased their target price on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Wells Fargo & Company initiated coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Thursday, December 19th.

Insider Buying and Selling at Savara

In related news, Director Joseph S. Mccracken bought 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares in the company, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. Choreo LLC purchased a new stake in shares of Savara in the second quarter worth about $59,000. DRW Securities LLC bought a new stake in Savara in the 2nd quarter worth approximately $62,000. Virtu Financial LLC purchased a new stake in shares of Savara during the 3rd quarter worth approximately $67,000. Principal Financial Group Inc. boosted its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC purchased a new position in shares of Savara in the second quarter valued at $105,000. Institutional investors own 87.93% of the company’s stock.

Savara Price Performance

SVRA stock opened at $3.05 on Wednesday. The company has a market cap of $523.44 million, a price-to-earnings ratio of -7.09 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The business’s 50-day moving average is $3.36 and its two-hundred day moving average is $3.91. Savara has a fifty-two week low of $2.82 and a fifty-two week high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). As a group, analysts forecast that Savara will post -0.45 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.